Idarubicin: all 111 studies that test it

Page 1 of 2. Open to participants first (17), then studies with results posted, then the rest; newest registration first within each.

• Study of the Effectiveness and Safety of Daunorubicin /Idarubicin ± Silibinin in Treating Newly Diagnosed AML (Non-M3).RecruitingNCT07561892Phase 4
• VA-CIG Regimen for Previously Untreated Acute Myeloid Leukemia: A Multicenter Prospective Single-Arm TrialRecruitingNCT07514832Phase 2
• MRD-positive AML Clinical StudyRecruitingNCT07131059Not applicable
• UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AMLRecruitingNCT07059975Early Phase 1
• Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid CancerRecruitingNCT07046078Phase 2
• Neoadjuvant Intra-tumor Double Immunotherapy for Lung Cancer.RecruitingNCT06492421Phase 2
• Neoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma.RecruitingNCT06492408Phase 2
• Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid LeukemiaRecruitingNCT06265545Not applicable
• Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AMLRecruitingNCT06221683Phase 2
• Reduced Intensive Idarubicin and Cytarabine Plus Venetoclax as First-line Treatment for Adults AML and MDSNot yet recruitingNCT06050941Phase 2
• Treateament of Newly Diagnosed Acute Monocytic Leukemia in ChildrenRecruitingNCT05313958Phase 2/3
• CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic LeukemiaRecruitingNCT04375631Phase 1
• Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeRecruitingNCT04047641Phase 1/2
• Childhood Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2015 (ALL-MB 2015)RecruitingNCT03390387Not applicable
• Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CRRecruitingNCT02416388Phase 2/3
• Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid LeukemiaRecruitingNCT02115295Phase 2
• Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeRecruitingNCT00801489Phase 2
• Relationship Between Plasma Concentration of Hydroxyprogesterone Caproate (17-OHPC) and Preterm BirthTerminatedNCT03292731Phase 1/2Results posted
• Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid LeukemiaCompletedNCT03226418Phase 2Results posted
• Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)CompletedNCT02464657Phase 1/2Results posted
• AML-02: Omacetaxine With Standard-of-Care Induction With Cytarabine & Idarubicin in Newly-Diagnosed AML PatientsTerminatedNCT02440568Phase 1/2Results posted
• A Phase II Study of Selinexor Plus Cytarabine and Idarubicin in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)CompletedNCT02249091Phase 2Results posted
• Chemoembolisation of Hepatocellular Carcinomas Not Subject to Interventive Care by Idarubicin-loaded Beads - IDASPHERE IICompletedNCT02185768Phase 2Results posted
• Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute LeukemiaCompletedNCT02135874Phase 2Results posted
• Guadecitabine With or Without Idarubicin or Cladribine in Treating Older Patients With Previously Untreated Acute Myeloid LeukemiaCompletedNCT02096055Phase 2Results posted
• Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid LeukemiaTerminatedNCT01876953Phase 1/2Results posted
• Idarubicin, Cytarabine, and Pravastatin Sodium in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic SyndromesCompletedNCT01831232Not applicableResults posted
• Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid LeukemiaCompletedNCT01802333Phase 3Results posted
• Decitabine Followed by Clofarabine, Idarubicin, and Cytarabine in Acute LeukemiaCompletedNCT01794702Phase 1/2Results posted
• E7070, Idarubicin and Cytarabine in Relapsed AML and High-Risk Myelodysplastic SyndromesCompletedNCT01692197Phase 2Results posted
• Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory AML and MDSTerminatedNCT01607645Phase 2Results posted
• Bendamustine and Idarubicin in Treating Older Patients With Previously Untreated AML or MDSCompletedNCT01141725Phase 1/2Results posted
• Clofarabine, Idarubicin, and Cytarabine Combination in Acute Myeloid Leukemia (AML) InductionCompletedNCT01025154Phase 2Results posted
• Trial of PXD101 (Belinostat) in Combination With Idarubicin to Treat AML Not Suitable for Standard Intensive TherapyCompletedNCT00878722Phase 1/2Results posted
• S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid LeukemiaCompletedNCT00840177Phase 2Results posted
• Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML)CompletedNCT00831766Phase 1/2Results posted
• Phase II Study of Idarubicin, Cytarabine, and Vorinostat With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)CompletedNCT00656617Phase 2Results posted
• A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT00620321Phase 2Results posted
• Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006)CompletedNCT00542971Phase 1/2Results posted
• Tretinoin and Arsenic Trioxide With or Without Idarubicin in Treating Patients With Acute Promyelocytic LeukemiaTerminatedNCT00528450Phase 2Results posted
• Idarubicin and High-Dose Cytarabine in Treating Patients With Acute Myeloid LeukemiaCompletedNCT00528398Phase 2Results posted
• Lestaurtinib, Cytarabine, and Idarubicin in Treating Younger Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT00469859Phase 1/2Results posted
• Standard Idarubicin and Cytarabine for the Treatment of Acute Myeloid Leukemia (AML)CompletedNCT00422591Phase 2Results posted
• Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid LeukemiaCompletedNCT00096122Phase 1/2Results posted
• Lipiodol-TACE With Idarubicin for Hepatocellular CarcinomaStatus unknownNCT05280444Phase 2/3
• Venetoclax + Decitabine vs. "7+3" Induction Chemotherapy in Young AMLActive, not recruitingNCT05177731Phase 3
• Bcl-2 Inhibitors Combined With Azacytidine and Chemotherapy in Elderly Patients With Previously Untreated AMLStatus unknownNCT05053425Not applicable
• Idarubicin vs. Epirubicin TACE in the Treatment of Hepatocellular CarcinomaStatus unknownNCT05053386Not applicable
• Venetoclax + Azacitidine vs. Induction Chemotherapy in AMLActive, not recruitingNCT04801797Phase 2
• Risk-adapted Therapy for Primary Acute Myeloid LeukemiaCompletedNCT04687098Phase 2
• Poly-ICLC (Hiltonol®) Vaccine In Malignant Pleural MesotheliomaCompletedNCT04525859Phase 1
• Comparing the Consolidation Regimens of IDA With Intermediate-dose Cytarabine Versus Intermediate-dose Cytarabine Alone for Elderly AML PatientsStatus unknownNCT04216771Phase 2/3
• Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid LeukemiaActive, not recruitingNCT04190550Phase 1
• Hepatocellular Carcinoma on Cirrhosis With Child A/B7 and Hepatic Intra Arterial Injection of Idarubicin/Lipiodol EmulsionTerminatedNCT03727633Phase 2
• Epacadostat, Idarubicin and Cytarabine (EIC) in AMLWithdrawnNCT03444649Phase 1
• Pevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid LeukemiaActive, not recruitingNCT03330821Phase 1/2
• Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and LymphomaActive, not recruitingNCT03117751Phase 2/3
• Efficacy of Idarubicin, Cytarabine and Cyclophosphamide (IAC) Regimen in Relapsed/Refractory AMLCompletedNCT02937662Phase 2
• Optimal Treatment Strategy Based on for Pediatric AMLStatus unknownNCT02848183Phase 2
• Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic LeukemiaCompletedNCT02779283Phase 1
• LY2510924, Idarubicin and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT02652871Phase 1
• Ibrutinib, Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT02635074Phase 1
• Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 MutationActive, not recruitingNCT02632708Phase 1
• Idarubicin at Different Dosages as Induction Therapy for Newly Diagnosed Acute Myeloid LeukaemiaStatus unknownNCT02277847Phase 4
• MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT02049801Phase 1
• Treatment of Cirrhosis-related Hepatocellular Carcinoma With the Intrahepatic Arterial Injection of an Emulsion of Lipiodol and Idarubicin (Zavedos®): Phase I StudyCompletedNCT02028949Phase 1
• Clinical Guidelines for APL TreatmentStatus unknownNCT02020161Phase 4
• Treatment Protocol of Children With Philadelphia Chromosome Negative High Risk Acute Lymphoblastic LeukemiaStatus unknownNCT01990807Phase 4
• Phase I/II Study of Escalating Doses of Idarubicin Orally Given With Oral Cyclophosphamide, Etoposide, Prednisolone and Intravenous Rituximab in Elderly Patient With Disseminated High Grade Non Hodgkin LymphomaCompletedNCT01958996Phase 1/2
• Sirolimus, Idarubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT01822015Early Phase 1
• Efficacy and Toxicity of Increasing Doses of Idarubicin, Cytarabine and G-CSF in Acute Myeloid LeukemiaCompletedNCT01700413Phase 2
• Dose Escalation of Clofarabine in Combination With Cytarabine and Idarubicin as Induction Therapy in High Risk AMLStatus unknownNCT01534702Phase 1/2
• Safety and Efficacy Study of Idarubicin Dose Intensification to Treat Acute Myeloid LeukemiaCompletedNCT01518556Phase 1/2
• Treatment of Relapsed or Refractory Acute Myeloblastic LeukemiaCompletedNCT01435343Phase 1/2
• Idarubicin Combined to Azacitidine in Int-2 or High Risk Myelodysplastic SyndromesCompletedNCT01305135Phase 1/2
• Lenalidomide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid LeukemiaCompletedNCT01132586Phase 1
• Chemoembolisation of Non Resectable, Non Metastatic Hepatocellular CarcinomasCompletedNCT01040559Phase 1
• A Study of Elacytarabine (CP-4055) Plus Idarubicin as Second Course Remission-Induction Therapy in Patients With Acute Myeloid LeukaemiaCompletedNCT01035502Phase 2
• Combination Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic LeukemiaCompletedNCT00967057Phase 3
• Trial for Localised High-risk Rhabdomyosarcoma and Rhabdomyosarcoma-like Soft Tissue SarcomaCompletedNCT00876031Phase 3
• Clofarabine, Cytarabine, and Idarubicin in Treating Patients With Intermediate-Risk or High-Risk Acute Myeloid Leukemia or High-Risk MyelodysplasiaStatus unknownNCT00838240Phase 1/2
• VELCADE in Combination With Idarubicin and Cytosine Arabinoside in Patients With Acute Myelogenous LeukemiaCompletedNCT00505700Phase 1
• Phase I Using Velcade & Idarubicin in Elderly and Relapsed AMLCompletedNCT00382954Phase 1
• Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic SyndromesCompletedNCT00331513Phase 1
• Salvage Therapy With Idarubicin in Relapsing CNS LymphomaTerminatedNCT00210366Phase 2
• German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003)CompletedNCT00198991Phase 4
• German Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic LeukemiaCompletedNCT00198978Phase 4
• Idarubicin Based Combined Modality Therapy in Primary CNS LymphomaCompletedNCT00193973Phase 2
• Total Therapy Study XIV for Newly Diagnosed Patients With Acute Lymphoblastic LeukemiaTerminatedNCT00187005Phase 3
• Thalidomide, Cyclophosphamide, Oral Idarubicin and Dexamethasone (T-CID) in Patients With Multiple MyelomaStatus unknownNCT00124813Phase 2
• Pravastatin, Idarubicin, and Cytarabine in Treating Patients With Acute Myeloid LeukemiaCompletedNCT00107523Phase 1
• Arsenic Trioxide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid LeukemiaCompletedNCT00093483Phase 1
• Study Evaluating the Addition of Amifostine (Ethyol®) to Idarubicin and Cytosine Arabinoside in Older Patients With Acute Myeloid LeukemiaCompletedNCT00086099Phase 1/2
• Idarubicin, Cytarabine, and Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Secondary to Myelodysplastic SyndromeCompletedNCT00077116Phase 2
• Bevacizumab, Idarubicin, and Cytarabine in Treating Patients With Blast Phase Chronic Myelogenous LeukemiaTerminatedNCT00023920Phase 2
• Combination Chemotherapy in Treating Children With Very High Risk Acute Lymphocytic LeukemiaCompletedNCT00003783Phase 2
• Combination Chemotherapy in Treating Patients With Relapsed Acute Myelogenous LeukemiaStatus unknownNCT00003758Phase 2
• Combination Chemotherapy in Treating Children With Relapsed or Refractory Acute Lymphocytic LeukemiaTerminatedNCT00003729Phase 2
• Combination Chemotherapy With or Without Interferon Alfa in Treating Patients With Low-Grade Non-Hodgkin's LymphomaStatus unknownNCT00003639Phase 3
• Chemotherapy Plus Steroid Therapy in Treating Patients With Multiple MyelomaStatus unknownNCT00003603Phase 3

← Idarubicin overview